Skip to main content
Main navigation
Home
About pCPA
Who We Are
Governance
Strategic Plan
Whats New at the pCPA
FAQs
Negotiations
Recent Updates
Forms and Publications
Brand Name Drugs
Negotiations Status
Negotiation Process
Generic Drugs
Biologics/Biosimilars
Contact Us
EN
FR
Vyndaqel (tafamidis)
pCPA File Number:
21922
Negotiation Status:
Concluded with an LOI
Indication(s):
Cardiomyopathy due to transthyretin-mediated amyloidosis
Sponsor/Manufacturer:
Pfizer Canada ULC
CADTH Project Number:
SF0722
pCPA Engagement Letter Issued:
2022-09-07
Negotiation Process Concluded:
2022-09-07